Related Experiment Videos
[Rapamycin and CCI-779]
J Alexandre1, E Raymond, J P Armand
1Département de médecine, Institut Gustave-Roussy, 94805 Villejuif Cedex.
Abstract:
Rapamycin (sirolimus) is a macrolide, related to cyclosporine with immunosuppressive properties and antiproliferative activity in various human tumor cells lines and tumor xenograft models. The cytosolic kinase mTOR which controls the initiation of the translation of messenger RNA is the main known target of rapamycin. During clinical studies, rapamycin given by oral route as immunosuppressant did not show dose-limited toxicity and only asymptomatic thrombopenia and hyperlipemia were observed. In murine models, best antitumoral activity was observed using parental routes. CCI-779, an analog formulated for intravenous use has antitumor activity without significant immunosuppressive property in mice and is currently in phase I trials in man.
Insights
Rapamycin, an immunosuppressant, shows antiproliferative effects against tumors. Its analog, CCI-779, demonstrates antitumor activity with reduced immunosuppression in preclinical models.
Area of Science:
- Pharmacology
- Oncology
- Immunology
Context:
- Rapamycin (sirolimus) is a macrolide with immunosuppressive and antiproliferative properties.
- It targets the mechanistic target of rapamycin (mTOR) kinase, crucial for protein synthesis.
- Clinical trials of oral rapamycin for immunosuppression showed manageable toxicity.
Purpose:
- To evaluate the antitumor potential of rapamycin and its analogs.
- To investigate the efficacy and safety of intravenous rapamycin formulations.
- To explore the relationship between immunosuppressive and antitumor activities.
Summary:
- Rapamycin exhibits antiproliferative activity in human tumor cell lines and xenografts.
- Oral rapamycin as an immunosuppressant had limited dose-related toxicity.
- Intravenous analog CCI-779 showed antitumor activity in murine models with minimal immunosuppression.
Impact:
- Rapamycin analogs like CCI-779 represent a promising therapeutic strategy for cancer treatment.
- Understanding mTOR inhibition offers new avenues for targeted cancer therapies.
- Further clinical investigation of CCI-779 is warranted for its antitumor potential.